RxDoctor Payments Data

Afif Elias, MD

Family Medicine · Bakersfield, CANPI 1558346346

Payments from drug & device makers

$2,865in general payments, 2019–2025

Across 158 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$911
  • GSK$397
  • Boehringer Ingelheim$318
  • Novo Nordisk$233
  • Lilly USA, LLC$225
  • AbbVie$131
  • plus $650 from 16 others

What the payments were for

  • Food & beverage$2,853100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,865 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$112,327
Medicare patients
163
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$79,921
FarxigaDapagliflozin Propanediol40$44,210
EliquisApixaban34$32,636
JardianceEmpagliflozin27$26,962
JanumetSitagliptin Phos/Metformin Hcl36$25,232
MounjaroTirzepatide24$24,342
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$23,865
TrulicityDulaglutide21$19,460
JanuviaSitagliptin Phosphate18$19,278
TradjentaLinagliptin13$10,701
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,270
Breo ElliptaFluticasone/Vilanterol14$6,225
Levothyroxine Sodium293$3,524
Rosuvastatin Calcium241$3,364
Atorvastatin Calcium304$2,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$233$79,92182 claims
MerckJanumet, Januvia$77$44,50954 claims
AstraZenecaFarxiga$911$44,21040 claims
Lilly USA, LLCMounjaro, Trulicity$225$43,80245 claims
Boehringer IngelheimJardiance, Tradjenta$318$37,66240 claims
PfizerEliquis$59$32,63634 claims
GSKTrelegy Ellipta, Breo Ellipta$397$30,09052 claims
AbbVieSynthroid$131$98214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →